Talk:CureVac

This is the talk page for discussing improvements to the CureVac article.
This is not a forum for general discussion of the article's subject.

Put new text under old text. Click here to start a new topic.
New to Wikipedia? Welcome! Learn to edit; get help.

Article policies

Find sources: Google (books · news · scholar · free images · WP refs) · FENS · JSTOR · TWL

Articles for creation Stub‑class

	This article was reviewed by member(s) of WikiProject Articles for creation. The project works to allow users to contribute quality articles and media files to the encyclopedia and track their progress as they are developed. To participate, please visit the project page for more information.Articles for creationWikipedia:WikiProject Articles for creationTemplate:WikiProject Articles for creationAfC articles
Stub	This article has been rated as Stub-class on Wikipedia's content assessment scale.
	This article was accepted on 25 April 2013 by reviewer Arthur goes shopping (talk · contribs).

The Wikimedia Foundation's Terms of Use require that editors disclose their "employer, client, and affiliation" with respect to any paid contribution; see WP:PAID. For advice about reviewing paid contributions, see WP:COIRESPONSE.

VerenaLauterbach CureVacAG (talk · contribs) has been paid by CureVacAG. Disclosed in username and at userpage.

Individuals with a conflict of interest, particularly those representing the subject of the article, are strongly advised not to directly edit the article. See Wikipedia:Conflict of interest. You may request corrections or suggest content here on the Talk page for independent editors to review, or contact us if the issue is urgent.

Request edit on 8 May 2018

This edit request has been answered. Set the |answered= or |ans= parameter to no to reactivate your request.

I would like to request the following change: CureVac has entered into a collaboration with Eli Lilly and Company in October 2017. This could be included in the list of partners at the beginning of the entry as well as in the history part. Neutral sources are e.g. https://endpts.com/eli-lilly-is-making-a-1-8b-leap-into-the-mrna-field-targeting-next-gen-cancer-vaccines/ and https://www.fiercebiotech.com/biotech/lilly-curevac-pen-1-8b-mrna-cancer-vaccine-deal Thank you for reviewing, --VerenaLauterbach CureVacAG (talk) 12:49, 8 May 2018 (UTC)[reply]

Reply 08-MAY-2018

"Entering into collaboration" is a vague assertion which leaves out salient details like the purpose for the collaboration, and why. The text may be placed within the article without clarification, however, a vague inline template would be added along with it. Please advise if this is acceptable.
Text within the article was found to be insufficiently paraphrased from the source material, and has been removed, per: WP:CLOSEPARAPHRASE. A listing of the text may be found here.
Additional text was found to be insuffciently paraphrased from the source material. This text was integral to the lead section and the beginning of the main body of text, so it was not removed. A listing of that text may be found here. in lieu of this removal, the close paraphrasing maintenance template was appended to the article.

When ready to proceed with your response to point No. 1 above, kindly change the request edit template to read from ans=yes to ans=no. Thank you! .spintendo⋅⋅) 13:42, 8 May 2018 (UTC)[reply]

Dear Spintendo,

Thank you for working on the article. Since other collaborations are now no longer included in the history part, Eli Lilly does not have to be included there either. However, it would still make sense in the list of partners at the beginning - would you then still need further details or add the vague inline template if it is just listed? I could provide them, if necessary.

How can I help to improve the article in order to discard the close paraphrasing and verification templates if I am not allowed to work in the article because of my COI? I would be grateful for advice.

--VerenaLauterbach CureVacAG (talk) 14:42, 8 May 2018 (UTC)[reply]

You can post specific suggestions here. If you want to add content, propose it here, formatted exactly like you would if you were editing directly in the article, with citations appropriately formatted, etc. It is like submitting a manuscript to a journal - it just happens all in public here on the talk page, instead of through email or the internet. Jytdog (talk) 14:46, 8 May 2018 (UTC)[reply]

Thank you, so I suggest to change

CureVac has entered into various collaborations with multinational corporations and organizations, including agreements with Boehringer Ingelheim...

to

CureVac has entered into various collaborations with multinational corporations and organizations, including agreements with Eli Lilly and Company^[1], Boehringer Ingelheim...

--VerenaLauterbach CureVacAG (talk) 15:26, 8 May 2018 (UTC)[reply]

References

^ https://endpts.com/eli-lilly-is-making-a-1-8b-leap-into-the-mrna-field-targeting-next-gen-cancer-vaccines/

Implemented The Lilly information was added to where you indicated, along with the reference. .spintendo⋅⋅) 18:22, 8 May 2018 (UTC)[reply]

Thank you! --VerenaLauterbach CureVacAG (talk) 05:55, 9 May 2018 (UTC)[reply]

Request edit on 17 May 2018

It is requested that an edit be made to the semi-protected article at A. (edit · history · last · links · protection log)

This template must be followed by a complete and specific description of the request, that is, specify what text should be removed and a verbatim copy of the text that should replace it. "Please change X" is not acceptable and will be rejected; the request must be of the form "please change X to Y".

The edit may be made by any autoconfirmed user. Remember to change the |answered=no parameter to "yes" when the request has been accepted, rejected or on hold awaiting user input. This is so that inactive or completed requests don't needlessly fill up the edit requests category. You may also wish to use the {{ESp}} template in the response. To request that a page be protected or unprotected, make a protection request.

I request the following edit: Please change

In September 2015, CureVac announced it would be opening a United States hub in Cambridge, Massachusetts.[18]

to

In September 2015, CureVac announced it would be opening a United States hub in Cambridge, Massachusetts[18] which moved to Boston later the same year.^[1]

--VerenaLauterbach CureVacAG (talk) 12:11, 17 May 2018 (UTC)[reply]

References

^ http://www.curevac.com/contact/

Implemented .spintendo⋅⋅) 17:17, 17 May 2018 (UTC)[reply]

Request edit on 18 May 2018

It is requested that an edit be made to the semi-protected article at A. (edit · history · last · links · protection log)

This template must be followed by a complete and specific description of the request, that is, specify what text should be removed and a verbatim copy of the text that should replace it. "Please change X" is not acceptable and will be rejected; the request must be of the form "please change X to Y".

The edit may be made by any autoconfirmed user. Remember to change the |answered=no parameter to "yes" when the request has been accepted, rejected or on hold awaiting user input. This is so that inactive or completed requests don't needlessly fill up the edit requests category. You may also wish to use the {{ESp}} template in the response. To request that a page be protected or unprotected, make a protection request.

I request the following edit: Please change

In 2016 CureVac will start the construction of an industrial scale production facility with a capacity of 30 million doses per year.[7]

to

In 2016, CureVac has started the construction of an industrial scale production facility with a capacity of 30 million doses per year.^[1]

References

^ https://www.in-pharmatechnologist.com/Article/2017/10/30/Curevac-starts-work-on-RNA-based-drug-plant-with-capacity-for-Lilly-deal

Thank you in advance, --VerenaLauterbach CureVacAG (talk) 09:01, 18 May 2018 (UTC)[reply]

Implemented It was not made clear what the "30 million doses" were of, so that part was omitted. If you clarify what this was, I can add it to the article. .spintendo⋅⋅) 15:50, 18 May 2018 (UTC)[reply]

Request edit on 18 May 2018

It is requested that an edit be made to the semi-protected article at CureVac. (edit · history · last · links · protection log)

This template must be followed by a complete and specific description of the request, that is, specify what text should be removed and a verbatim copy of the text that should replace it. "Please change X" is not acceptable and will be rejected; the request must be of the form "please change X to Y".

The edit may be made by any autoconfirmed user. Remember to change the |answered=no parameter to "yes" when the request has been accepted, rejected or on hold awaiting user input. This is so that inactive or completed requests don't needlessly fill up the edit requests category. You may also wish to use the {{ESp}} template in the response. To request that a page be protected or unprotected, make a protection request.

I request the following edit: Please change

Since inception, CureVac had received approximately $330 million (€300 million) in equity investments.[3]

to

Since inception, CureVac had received approximately $360 million (€300 million) in equity investments and has a valuation of $1.65 billion (status October 2017)^[1] and thus is classified as a Unicorn (finance).

References

^ https://www.nanalyze.com/2017/10/8-biggest-startups-europe/

Thank you, --VerenaLauterbach CureVacAG (talk) 09:26, 18 May 2018 (UTC)[reply]

Implemented I am working on rewriting the text which needs to be paraphrased, so that the maintenance template may be removed. Expect that shortly. .spintendo⋅⋅) 15:50, 18 May 2018 (UTC)[reply]

The problematic, insufficiently paraphrased sentences have been addressed (a description of these is in the edit summary) and the Close paraphrase maintenance template has been removed. .spintendo 02:35, 23 May 2018 (UTC)[reply]

Thank you so much for rewriting the text and removing the template. Unfortunately, the sentence is now a bit misleading (it had already been ambiguous before): What we develop are prophylactic vaccines in the area of infectious diseases (e.g. vaccines against rabies) as well as therapeutic vaccines in the areas oncology (Cancer immunotherapy) and rare diseases (e.g. Ornithine transcarbamylase deficiency). I suggest to change the sentence as follows:

The company's focus is on developing prophylactic treatment for diseases of infection, primarily through the use of vaccines, as well as therapeutic treatment for cancer and rare diseases.

Since rare diseases have not yet been part of our research when the named source was published in 2012, this article could be added as source: https://www.thepharmaletter.com/article/new-mrna-partnership-in-rare-diseases

Thank you for reviewing, --VerenaLauterbach CureVacAG (talk) 10:12, 23 May 2018 (UTC)[reply]

Request edit on 23 May 2018

It is requested that an edit be made to the semi-protected article at CureVac. (edit · history · last · links · protection log)

This template must be followed by a complete and specific description of the request, that is, specify what text should be removed and a verbatim copy of the text that should replace it. "Please change X" is not acceptable and will be rejected; the request must be of the form "please change X to Y".

The edit may be made by any autoconfirmed user. Remember to change the |answered=no parameter to "yes" when the request has been accepted, rejected or on hold awaiting user input. This is so that inactive or completed requests don't needlessly fill up the edit requests category. You may also wish to use the {{ESp}} template in the response. To request that a page be protected or unprotected, make a protection request.

Since the link of source no. 18 ("Sequence Engineered mRNA Without Chemical Nucleoside Modifications...") does not work any more, I suggest to replace it with the current link: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4817881/ Thanks, --VerenaLauterbach CureVacAG (talk) 11:33, 23 May 2018 (UTC)[reply]

[1] ttps://endpts.com/eli-lilly-is-making-a-1-8b-leap-into-the-mrna-field-targeting-next-gen-cancer-vaccines/

[2] ttp://www.curevac.com/contact/

[3] ttps://www.in-pharmatechnologist.com/Article/2017/10/30/Curevac-starts-work-on-RNA-based-drug-plant-with-capacity-for-Lilly-deal

[4] ttps://www.nanalyze.com/2017/10/8-biggest-startups-europe/

[1]

[1]

[1]

[1]